Press Release

PharmAla Issues Q3 Financial Statements

Toronto, Ontario – July 25, 2025 - PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial and operational results for the period ended May 31, 2025. All figures are reported in Canadian dollars. The Company’s full set of unaudited condensed interim consolidated financial statements for the quarter and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at www.PharmAla.ca and its profile page on SEDAR+ at www.sedarplus.ca.

“The re-opening of PharmAla’s domestic Canadian distribution has allowed us to execute as much volume in Q2 and Q3 as we did in all of the last fiscal year. The creation of our Prescriber’s Portal has also allowed us to build a much closer relationship with our doctor customers, which we believe will serve us well moving forward,” said Nick Kadysh, CEO, PharmAla Biotech. “As we move into the last quarter of Fiscal ’24-25, we are incredibly pleased that a large shipment of LaNeo MDMA has arrived at our US distribution partner for delivery to a considerable group of clinical trial customers, most previously announced. PharmAla is also pleased to announce the completion of a manufacturing run in Australia for our 40mg LaNeo Capsules. These capsules were jointly manufactured for both Cortexa’s use within Australia and PharmAla’s use worldwide, and our improved manufacturing process should yield operational benefits well into the future.”

Financial Highlights:

  • Customer deposits have continued to grow by $150,463 through Q3, offset by recognition of revenue of $79,558. These deposits, generally being 50% of the total contract value, can be recognized along with the remaining revenue when the related product is shipped, which for many customers requires the issuance of their clinical trial and/or import permits from relevant regulatory bodies.

  • Shipments in Canada under the SAP were resumed in Q2 despite no SAP sales in Q1, through Q3 we are approaching the level of SAP sales completed in fiscal 2024.

  • Having established a repeatable export process during Q2 and having secured the requisite Health Canada export permits, we fulfilled further U.S. clinical trial sales during Q3. Including SAP revenue, during the 3 and 9 months ended June 30, 2025, we recognized $79,408 and $168,289 of product revenue.

  • Total expenses for the nine months ended May 31, 2025 and 2024 of $2,117,495 and $1,085,458, respectively, in addition to cost of sales of $19,123 and $296,962, respectively, and the effect of non-cash expenses (bad debt expense, depreciation and amortization, stock based compensation and loss on debt settlement, collectively $988,811 and $345,101), the increase in the remaining expenses is approximately $110,000. The increase is primarily due to the hiring of our Chief Commercial Officer, Chief Financial Officer and the cessation of capitalization of research and development costs related to MDXX molecules, which is partially offset by better cost management elsewhere.

“Over the past quarter, our team has made exciting progress to ensure a reliable supply of pharmaceutical product for both researchers in clinical trials and patients in need of treatment,” said Will Avery, CFO, PharmAla Biotech. “Our Prescriber Platform continues to empower physicians to access the MDMA and provide treatment for their patients and we look forward to additional clinical trial fulfillment to US and international customers in the near term, unburdened by cross-border trade issues.”

About PharmAla

PharmAla Biotech Holdings Inc. (CSE: MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials, and to develop novel drugs in the same class. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. Our team of dedicated professionals includes regulatory experts, scientists, and biomanufacturing professionals. PharmAla has built what it believes to be North America’s first cGMP MDMA value chain, encompassing GMP manufacturing of Active Pharmaceutical Ingredient (API), and drug product formulation. PharmAla’s research and development unit has also begun preclinical research into two patented Novel Chemical Entities (NCEs) based on MDXX class molecules, with proof-of-concept research currently ongoing at the University of Arkansas Medical School.

Media Inquiries

Nicholas Kadysh, CEO
press@pharmala.ca